Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan

Oncotarget. 2017 Jan 3;8(1):1083-1091. doi: 10.18632/oncotarget.13565.

Abstract

The prognostic role of modified Glasgow Prognostic Score (mGPS), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with salivary duct carcinoma (SDC) remains unclear. We conducted a multi-institutional retrospective cohort study of 140 SDC patients. The survival impact of these hematological markers was evaluated using multivariate proportional hazard models.High mGPS (≥1) was significantly associated with worse survival (3-year overall survival (OS): 16.7% vs 66.1%, p-value=0.003; 3-year progression-free survival (PFS): 0.0% vs 27.9%, p-value<0.001). Additionally, high C-reactive protein (CRP) (≥0.39 mg/dl) was significantly associated with worse survival (3-year OS: 32.1% vs 68.2%, p-value=0.001; 3-year PFS: 7.1% vs 31.1%, p-value<0.001). These associations were consistent with multivariate analysis adjusted for established prognostic factors. Although we also found significant association of high NLR (≥2.5) with OS (HR 1.80; 95% confidence interval, 1.05-3.08) in multivariate analysis, this association were inconsistent with the results of PFS. In addition, we found no significant associations of PLR with survival. In conclusion, we found that mGPS, CRP and NLR were identified as prognostic factors associated with survival in SDC patients.

Keywords: CRP; NLR; mGPS; salivary duct carcinoma; survival.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood*
  • Female
  • Humans
  • Inflammation Mediators / blood*
  • Japan
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Prognosis
  • Salivary Ducts / pathology*
  • Salivary Gland Neoplasms / blood*
  • Salivary Gland Neoplasms / diagnosis
  • Salivary Gland Neoplasms / mortality*
  • Salivary Gland Neoplasms / therapy

Substances

  • Biomarkers
  • Inflammation Mediators